Browse > Article
http://dx.doi.org/10.7314/APJCP.2016.17.3.1009

Effects of TNFalpha, NOS3, MDR1 Gene Polymorphisms on Clinical Parameters, Prognosis and Survival of Multiple Myeloma Cases  

Basmaci, C (Department of Hematology, Gaziantep University Faculty of Medicine)
Pehlivan, M (Department of Hematology, Gaziantep University Faculty of Medicine)
Tomatir, AG (Department of Medical Biology, Pamukkale University, Faculty of Medicine)
Sever, T (Department of Medical Biology and Genetics, Gaziantep University Faculty of Medicine)
Okan, V (Department of Hematology, Gaziantep University Faculty of Medicine)
Yilmaz, M (Department of Hematology, Gaziantep University Faculty of Medicine)
Oguzkan-Balci, S (Department of Medical Biology and Genetics, Gaziantep University Faculty of Medicine)
Pehlivan, S (Department of Medical Biology, Istanbul University, Istanbul Medical Faculty)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.17, no.3, 2016 , pp. 1009-1014 More about this Journal
Abstract
It is not clear how gene polymorphisms affecting drugs can contributes totheir efficacy in multiple myeloma (MM). We here aimed to explore associations among gene polymorphisms of tumor necrosis factor alpha (TNFalpha), nitric oxide synthesis 3 (NOS3) and multi-drug resistance 1 (MDR1), clinical parameters, prognosis and survival in MM patients treated with VAD (vincristine-adriamycine-dexamethasone), MP (mephalane-prednisolone), autolougus stem cell transplantation (ASCT), BODEC (bortezomib-dexamethasone-cyclophosphamide) and TD (thalidomide-dexamethasone). We analyzed TNFalpha, NOS 3 and MDR1 in 77 patients with MM and 77 healthy controls. The genotyping was performed with PCR and/or PCR-RFLP. There was no clinically significant difference between MM and control groups when TNFalpha (-238) and (-857) and MDR1 gene polymorphisms were studied. However, the TNFalpha gene polymorphism (-308) GG genotype (p=0.012) and NOS3 (+894) TT genotype (p=0.008) were more common in the MM group compared to healthy controls. NOS3 (VNTR) AA (p=0.007) and NOS3 (+894) GG genotypes (p=0.004) were decreased in the MM group in contrast. In conclusion, the NOS3 (+894) TT and TNFalpha (-308) GG genotypes may have roles in myeloma pathogenesis.
Keywords
Multiple myeloma; NOS3 (+894, VNTR); TNFalpha (-308, -238 and -857); MDR1;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Akcali A, Pehlivan S, Pehlivan M, et al (2010). TNF-alpha promoter polymorphisms in multiple sclerosis: no association with -308 and -238 alleles, but the -857 alleles in associated with the disease in Turkish patients. Int J Immunogenet, 37, 91-5.   DOI
2 Banu C, Moise A, Arion CV, et al (2011). Cytokine Gene Polymorphisms support diagnostic monitoring of Romanian Multiple Myeloma patients. J Med Life, 4, 264-8.
3 Bivalacqua TJ, Champion HC, Hellstrom WJG (2002). Implications of nitric oxide synthases isoforms in the pathophysiology of Peyronie’s disease. Int J Imp Res, 14, 345-2.   DOI
4 Black RA, Rauch CT, Kozlosky CJ, et al (1997). A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature, 385, 729-33.   DOI
5 Buda G, Maggini V, Galimberti S, et al (2007). MDR1 polymorphism influences the outcome of multiple myeloma patients. Br J Haematol. 137, 454-6.   DOI
6 Buda G, Ricci D, Huang CC, et al (2010). Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Ann Hematol. 89, 1133-40.   DOI
7 Cox DR (1972). Regression models and life-tables. J R Stat Soc Ser B, 34, 187-220.
8 Dogra S, Khullar G (2013). Tumor necrosis factor-${\alpha}$ antagonists: Side effects and their management. Indian J Dermatol Venereol Leprol, 7, 35-46.
9 Drain S, Catherwood MA, Orr N, et al (2009). ABCB1 (MDR1) rs1045642 is associated with increased overall survival in plasma cell myeloma. Leuk Lymphoma, 50, 566-570.   DOI
10 Du J, Yuan ZG, Zhang CY, et al (2009). Effect of TNF-alpha gene polymorphism on outcome of thalidomide-based regimens for multiple myeloma. Zhonghau Xue Ye Xeu Za Zhi, 30, 649-53.
11 Game X, Rischmann P, Arnal JF, et al (2013). Nitric oxide pathway and female lower urinary tract. Physiological and pathophysiological role]. Prog Urol, 23, 926-35.   DOI
12 Germann, UA (1996). P-glycoprotein--a mediator of multidrug resistance in tumour cells. Eur J Cancer. 32, 927-44.   DOI
13 Ghilardi G, Biondi ML, Cecchini F, et al (2003). Vasculer invasion in human breast cancer is coralated to T->786C polymophism of NOS3 gene. Nitric Oxide, 9, 118-22.   DOI
14 Hefler LA, Grimm C, Lantzsch T, et al (2006). Polymorphisms of the endothelial nitric oxide synthase gene in breast cancer. Breast Cancer Res Treat, 98, 151-55.   DOI
15 Hefler LA, Ludwig E, Lampe D, et al (2002). Polymorphisms of the endothelial nitric oxide synthase gene in ovarian cancer. Gynecol Oncol, 86,134-37.   DOI
16 Heil M, Eitenmuller I, Schmitz-Rixen T, et al (2006). Arteriogenesis versus angiogenesis: similarities and differences. J Cell Mol Med, 10, 45-55.   DOI
17 Ichimaru M, Ishimaru T, Mikami M, et al (1982). Multiple myeloma among atomic bomb survivors in Hiroshima and Nagasaki, 1950-76: Relationship to radiation dose absorbed by marrow. J Natl Cancer Inst, 69, 323-28.
18 Iokupova EV, Grinchuk OV, Kalimullina DKh, et al (2003). Molecular genetic analysis of the IL-6 and Tumor necrosis factor alpha gene polymorphisms in multiple myeloma. Mol Biol (Mosk), 37, 420-24.
19 Juliano RL, Ling VA (1976). Surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta, 455, 152-62.   DOI
20 Jamroziak K, Balcerczak E, Cebula B, et al (2005). Multi-drug transporter MDR1 gene polymorphism and prognosis in adult acute lymphoblastic leukemia. Pharmacol Rep, 57, 882-8.
21 Kadar K, Kovacs M, Karadi I, et al (2008). Polymorphism of TNF-alpha and LT-alpha genes in multiple myeloma. Leuk Res. 32, 1499-504.   DOI
22 Kaplan EL, Meier P (1958). Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53, 457-81.   DOI
23 Knop S (2014). The multiple myeloma - current view and perspectives. Med Monatsshr Pharm, 37, 84-92.
24 Kyle RA (1994). Multiple myeloma: How did it begin? Mayo Clin Proc, 69, 680-83.   DOI
25 Medeiros R, Morais A, Vasconcelos A, et al (2002). Endothelial nitric oxide synthase gene polymorphisms and genetic susceptibility to prostate cancer. Eur J Cancer Prev, 11, 343-50.   DOI
26 Nakamura K, Matsuzawa N, Ohmori S, et al (2013). Clinical Evidence of Pharmacokinetic Changes in Thalidomide Therapy. Drug Metab Pharmacokinet, 28, 38-43.   DOI
27 Nathan C, Xie QW (1994). Nitric oxide synthases. Roles, tolls and controls. Cell, 78, 915-8.   DOI
28 Neben K, Mytilineos J, Moehler TM, et al (2002). Polymorphisms of the tumor necrosis factor-${\alpha}$ gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood, 100, 2263-65.
29 Riener EK, Hefler LA, Grimm C, et al (2004). Polymorphisms of the endothelial nitric oxide synthase gene in women with vulvar cancer. Gynecol Oncol, 93, 686-90.   DOI
30 Olmos G, Llado J (2014). Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity. Mediators Inflamm, 2014, 861231.
31 Wajant H, Pfizenmaier K, Scheurich P (2003). Tumor necrosis factor signaling. Cell Death Differ, 10, 45-65.   DOI
32 Wang SS, Davis S, Cerhan JR, et al (2006). Polymorphisims in oxidative stres genes and risk for non-Hodgkin lymphoma. Carcinogenesis, 27, 1828-34.   DOI